



Bexion Partners with Molecular Targeting Technologies on Novel Cancer Imaging Agent

West Chester, PA, April 22, 2008 – Molecular Targeting Technologies, Inc. (MTTI) announced today that they have agreed to collaborate with Bexion Pharmaceuticals, LLC (Bexion) to develop a novel nanovesicle for molecular imaging of tumors.

Bexion has demonstrated that specific versions of these nanovesicles can be used to selectively target a broad range of tumors (both solid and hematologic). Specific formulations have also demonstrated the potential for treatment of a wide range of human cancers, including gliomas, prostate and pancreatic cancer.

“This novel nanovesicle technology will dramatically augment our ability to accurately diagnose and provide timely cancer treatment. Our initial indication will be focused on gliomas,” said Dr. Chris Pak, President and CEO of MTTI.

Dr. Ray Takigiku, President & CEO of Bexion said, “We are delighted to be collaborating with MTTI for progressing our nanovesicle technology for the development of preclinical and clinical diagnostic imaging reagents. We are always working to optimize treatment options.”

“We will develop dual modality diagnostics using this technology. The ability to visualize the tumor by two imaging modalities offers a new approach for monitoring and accurate resection of tumors,” said Dr. Brian Gray, Vice President of Research of MTTI.

Molecular Targeting Technologies, Inc. (MTTI) is a privately held US-based biotechnology company founded to develop novel medical imaging products for the diagnosis and treatment of cardiovascular disease and cancer. The company has further expanded its technology to include novel recombinant rabies vaccines for vaccination of wildlife, human anti-rabies monoclonal antibodies for post-exposure prophylaxis, and a fusion protein technology for improved anthrax and botulinum toxin vaccines. MTTI has recently licensed worldwide rights to manufacture, sell and/or distribute innovative proprietary fluorescence based technologies and novel bead based technologies from PTI Research Inc. (PTIR).

Bexion Pharmaceuticals, LLC is a privately held company developing cures for cancer. The Company has a first-in-class biologic product with data-driven potential for treatment of a broad range of human cancers. Specifically, Bexion is focused on the development of therapeutics for treating gliomas, possibly simultaneously with other solid tumors.

Contact:

Jeffrey Mattis, Ph.D., jmattis@mtarget.com, (610)-738-7938

Ray Takigiki, Ph.D., rtakigiku@bexionpharma.com, (513)-807-0574